Solid Biosciences Valuation Multiples

Solid Biosciences Overview

About Solid Biosciences

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company’s singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Founded

2013

HQ

Employees

100

Website

solidbio.com

Sectors

BiopharmaceuticalsBioTechDeepTech

Financials (LTM)

Revenue: —

EBITDA: ($187M)

EV

$269M

Valuation Multiples

Multiples.vc

Start free trial

Solid Biosciences Financials

Solid Biosciences reported last 12-month revenue of — and negative EBITDA of ($187M).

In the same LTM period, Solid Biosciences generated ($187M) in EBITDA losses and had net loss of ($181M).

Solid Biosciences P&L

In the most recent fiscal year, Solid Biosciences reported revenue of — and EBITDA of ($122M).

Solid Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX

Solid Biosciences Stock Performance

Solid Biosciences has current market cap of $483M, and enterprise value of $269M.

Solid Biosciences' stock price is $6.20.

Solid Biosciences Valuation Multiples

Solid Biosciences trades at (1.4x) EV/EBITDA.

Solid Biosciences Financial Valuation Multiples

As of March 21, 2026, Solid Biosciences has market cap of $483M and EV of $269M.

Equity research analysts estimate Solid Biosciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Solid Biosciences has a P/E ratio of (2.7x).

Solid Biosciences Margins & Growth Rates

Solid Biosciences' revenue in the last fiscal year grew by —.

Solid Biosciences' revenue per employee in the last FY averaged $0.0M.

Solid Biosciences Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Solid Biosciences M&A Activity

Solid Biosciences acquired XXX companies to date.

Last acquisition by Solid Biosciences was on XXXXXXXX, XXXXX. Solid Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Solid Biosciences Investment Activity

Solid Biosciences invested in XXX companies to date.

Solid Biosciences made its latest investment on XXXXXXXX, XXXXX. Solid Biosciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).